FluoGuide

Executive Summary

FluoGuide A/S is a clinical-stage biotechnology company based in Copenhagen, Denmark, focused on improving cancer surgery outcomes through targeted fluorescent drugs. Its lead product, FG001, is an intraoperative imaging agent designed to illuminate cancerous tissue in real time, enabling surgeons to achieve more precise resections. By reducing cancer recurrence and surgical complications, FluoGuide aims to lower overall healthcare costs while improving patient outcomes. The company is privately held and has not disclosed its total funding or valuation, but its technology addresses a critical unmet need in oncology surgery. FluoGuide is currently advancing FG001 through clinical development, with initial studies expected to demonstrate safety and efficacy in specific cancer types. If successful, FG001 could become a standard adjunct in surgical oncology, offering a competitive advantage over existing techniques such as frozen section analysis or other fluorescence agents. Key risks include the need for robust clinical data, regulatory approval, and adoption by surgeons. The company's near-term focus is on completing early-stage trials and establishing partnerships for manufacturing or commercialization. Overall, FluoGuide represents an innovative approach to cancer surgery with significant potential market impact.

Upcoming Catalysts (preview)

• Q2 2026Phase 1/2 Clinical Data Readout for FG00170% success
• Q4 2026Regulatory Approval for Expanded Trial (e.g., IND filing in US)60% success
• Q2 2027Strategic Partnership with Surgical Technology Company50% success